Ancora university1/29/2024 in pathology from Vanderbilt University.ĭeerfield Management and Vanderbilt University announce the launch of Ancora Innovation In cell biology from University of Tennessee and a Ph.D. Proof-of-concept studies, and bringing a first-in-class drug to market. Margaret brings extensive experience in drug discovery and development toĪncora Innovation, including filing IND’s, leading cross-functional project teams through clinical Before joining industry, Margaret was an instructor and research fellow at She started her career in drug discovery at ProScript as a senior scientist and leader of theĬell Cycle team. Led Cell and Molecular Oncology and was the discovery leader on the VelcadeTM product development team. Prior to Infinity, she was a director at Millennium Pharmaceuticals where she Margaret previously served as vice president of Portfolio and Product Development at Infinity Prior to joining Ancora Innovation, she wasĪn independent consultant in the oncology sector for biotechnology and pharmaceutical companies. Margaret is the Alliance Manager for Ancora Innovation. Danishefsky with funding from anĪmerican Cancer Society research fellowship. Studies at Yale University under the sponsorship of Samuel J. University of Pennsylvania under the mentorship of Amos B. Over 50 undergraduate researchers over his 25-year academic career. graduate students and has also mentored 16 postdoctoral researchers and As co-PI of the VCCDD, Gary has worked within team science drugĭiscovery projects with a variety of centers including UCSF, SRI international and the National Centerįor Advancing Translational Sciences (part of the NIH). Modulators of GIRK (G-protein Inward Rectifying Potassium) ion channels, small molecule regulators ofĬircadian rhythms, small molecule regulators of bacterial two-component systems and synthesis/study of He is currently investigating the development of small molecule His current research program continues to encompass the study ofĬomplex natural products with an added emphasis on the biology associated with select natural productsĪnd synthetic small molecules. The Director of the Vanderbilt Institute of Chemical Biology, and the co-PI of the Vanderbilt Centerįor Cancer Drug Discovery (VCCDD). Gary is the Stevenson Professor of Chemistry at the Vanderbilt University Department of Chemistry, Of the Association of University Technology Managers (AUTM) and the Licensing Executives Society (LES). Illinois -Urbana and a doctorate in Molecular Biology from Loyola University Chicago. Sciences background, which includes a bachelor’s degree in Microbiology from the University of Mike was a Senior Process Scientist at Abbott Laboratories where he oversaw the manufacturing ofĭiagnostic assays for human blood borne pathogens, namely Hepatitis B and C. Mike is a seasoned licensing professional with overġ5 years of experience bringing early-stage life science and medical device technologies to theĬommercial markets through licensing and co-development partnerships. Prior to joining Vanderbilt, he managed the commercialization of technologiesįor The Cleveland Clinic and Purdue University. Responsible for commercializing therapeutic, medical device and diagnostic technologies throughĬorporate partnerships. Mike joined Vanderbilt University in September 2011 to head up the Biotech Licensing Team and is Of Health, with certifications in internal medicine, pulmonary medicine, and anesthesiology. Ken received his medical and research training at Johns Hopkins University and the National Institutes Pharmaceutical and medical device industries at Vanderbilt’s Owen School of Management MBA program. He continues a part time clinical practice in anesthesiology, and has taught courses on the In 2005, Ken was COO with former NASDAQ company Genaera Pharmaceuticals. Vanderbilt Accelerating Drug Discovery and Repurposing Incubator. Health, and the Tennessee Technology Development Corporation. Human Vaccines Project, Informatics Corporation of America, DigiChart, Acuitec, Friends in Global Ken has served as the Vanderbilt representative on theīoard of Directors for Cumberland Emerging Technologies (a division of Cumberland Pharmaceuticals), Professor of Anesthesiology and Medicine. Ken is Vice President for Technology Transfer at Vanderbilt University Medical Center, Medical Directorįor the Vanderbilt University Center for Technology Transfer and Commercialization, and Associate
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |